Dr. Dr. Daniel Horber
Medizinische Onkologie und Hämatologie · Dept. I
Choice of first line systemic treatment in pancreatic cancer among national experts
Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020; 20 (2020):686-690.
Mar 31, 2020Choice of first line systemic treatment in pancreatic cancer among national experts
Mar 31, 2020Pancreatology 2020; 20 (2020):686-690
Glatzer Markus, Pless Miklos, Pederiva S., Pestalozzi Bernhard, Berger M.D., Inauen Roman, Winterhalder Ralf, Montemurro Michael, Horber Daniel, Putora Paul Martin
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol 2018; 10:304-310.
Dec 14, 2018Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Dec 14, 2018J Geriatr Oncol 2018; 10:304-310
Kienle Dirk L, Andrieu Christiane, Bernhard Juerg, Lugli Alessandro, Baertschi Daniela, Helbling Daniel, Saletti Piercarlo, Kueng Marc, Bastian Sara, Horber Daniel, Koeberle Dieter, Winterhalder Ralph C, Quagliata Luca, Wicki Andreas, Ribi Karin, Dietrich Daniel, von Moos Roger
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Burmeister K, Tornillo L, Piscuoglio S, Ng C, Köberle D, Lehmann F, Moosmann P, Horber D, Jochum W, Grobholz R, Perrina V, Matter M, Eppenberger-Castori S, Andreozzi M, Quagliata L, Terracciano L. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PloS one 2017; 12:e0175563.
Apr 12, 2017Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Apr 12, 2017PloS one 2017; 12:e0175563
Burmeister Katharina, Tornillo Luigi, Piscuoglio Salvatore, Ng Charlotte K Y, Köberle Dieter, Lehmann Frank, Moosmann Peter, Horber Daniel, Jochum Wolfram, Grobholz Rainer, Perrina Valeria, Matter Matthias S, Eppenberger-Castori Serenella, Andreozzi Mariacarla, Quagliata Luca, Terracciano Luigi M
Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clin Colorectal Cancer 2017
Mar 21, 2017Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
Mar 21, 2017Clin Colorectal Cancer 2017
Fehr Martin, Müller Joachim, Knitel Meinhard, Fornaro Jürgen, Horber Daniel, Koeberle Dieter, Cerny Thomas, Gueller Ulrich
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
Koeberle D, Tschanz B, Rauch D, Peck-Radosavljevic M, Veilchenfeldt J, Lakatos G, Montemurro M, Wagner A, Buehlmann M, Horber D, Roth A, Saletti P, Samaras P, Ribi K, Li Q, Demeter G, Dufour J, Bodocky G. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol 2016; 27:856-861.
May 2, 2016Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
May 2, 2016Ann Oncol 2016; 27:856-861
Koeberle D., Tschanz B., Rauch D., Peck-Radosavljevic M., Veilchenfeldt J., Lakatos G., Montemurro M., Wagner A.D., Buehlmann M., Horber Daniel, Roth A.D., Saletti P., Samaras P., Ribi K., Li Q., Demeter G., Dufour J.F., Bodocky G.
Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients
Tarantino I, Achermann P, Gueller U, Ulrich A, Schmied B, Horber D, Cerny T, Stanga Z, Warschkow R. Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients. Ann Surg Oncol 2013; 20:3877-2884.
Aug 2, 2013Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients
Aug 2, 2013Ann Surg Oncol 2013; 20:3877-2884
Tarantino Ignazio, Achermann Philipp, Gueller Ulrich, Ulrich Alexis, Schmied Bruno, Horber Daniel, Cerny Thomas, Stanga Zeno, Warschkow Rene
Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice
Rentsch K, Horber D, Schwendener R, Wunderli-Allenspach H, Haenseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer 1997; 75:986-992.
Jan 1, 1997Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice
Jan 1, 1997Br J Cancer 1997; 75:986-992
Rentsch K.M., Horber Daniel, Schwendener R., Wunderli-Allenspach H., Haenseler E.
Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Schwendener R, Horber D, Odermatt B, Schott H. Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 1996; 122:102-108.
Jan 1, 1996Oral antitumor activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine (ara-C)
Jan 1, 1996J Cancer Res Clin Oncol 1996; 122:102-108
Schwendener R., Horber Daniel, Odermatt B., Schott H.
Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, von Ballmoos P, Schott H, Schwendener R. Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 72:1067-1073.
Nov 1, 1995Cell cycle dependent cytotoxicity and induction of apoptosis by N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Nov 1, 1995Br J Cancer 1995; 72:1067-1073
Horber Daniel, von Ballmoos P., Schott H., Schwendener R.
Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Horber D, Ottiger C, Schott H, Schwendener R. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 1995; 47:282-288.
Apr 12, 1995Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes
Apr 12, 1995J Pharm Pharmacol 1995; 47:282-288
Horber Daniel, Ottiger C., Schott H., Schwendener R.
Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Horber D, Schott H, Schwendener R. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. Br J Cancer 1995; 71:957-962.
Jan 1, 1995Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine
Jan 1, 1995Br J Cancer 1995; 71:957-962
Horber Daniel, Schott H., Schwendener R.
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Horber D, Schott H, Schwendener R. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 1995; 36:483-492.
Jan 1, 1995Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937
Jan 1, 1995Cancer Chemother Pharmacol 1995; 36:483-492
Horber Daniel, Schott H., Schwendener R.
Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC
Schwendener R, Horber D, Ottiger C, Rentsch K, Fiebig H, Schott H. Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC. Drugs of the Future 1995; 20:11-15.
Jan 1, 1995Monograph: Alkasar-18, 1-(beta-D-arabinofuranosyl)-4-octadecylamino-2(1H)-pyrimidin-one, N4-octadecyl-ara-C, NOAC
Jan 1, 1995Drugs of the Future 1995; 20:11-15
Schwendener R., Horber Daniel, Ottiger C., Rentsch K.M., Fiebig H.H., Schott H.
Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations
Schwendener R, Horber D, Ottiger C, Schott H. Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations. J Liposome Res 1995; 5:27-47.
Jan 1, 1995Preclinical properties of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabino-furanosylcytosine in liposomal preparations
Jan 1, 1995J Liposome Res 1995; 5:27-47
Schwendener R., Horber Daniel, Ottiger C., Schott H.
Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer
Pestalozzi B, Vass A, Adam H, Horber D, Schwendener R, Sauter C. Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur J Cancer 1995; 31A:1024.
Jan 1, 1995Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer
Jan 1, 1995Eur J Cancer 1995; 31A:1024
Pestalozzi B., Vass A., Adam H., Horber Daniel, Schwendener R., Sauter C.
New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens
Schwendener R, Gowland P, Horber D, Zahner R, Schertler A, Schott H. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Res 1994; 24:79-93.
May 1, 1994New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens
May 1, 1994Antiviral Res 1994; 24:79-93
Schwendener R., Gowland P., Horber Daniel, Zahner R., Schertler A., Schott H.
Preclinical and clinical experience with liposome encapsulated mitoxantrone
Schwendener R, Horber D, Rentsch K, Haenseler E, Pestalozzi B, Sauter C. Preclinical and clinical experience with liposome encapsulated mitoxantrone. J Liposome Res 1994; 4:605-639.
Jan 1, 1994Preclinical and clinical experience with liposome encapsulated mitoxantrone
Jan 1, 1994J Liposome Res 1994; 4:605-639
Schwendener R., Horber Daniel, Rentsch K.M., Haenseler E., Pestalozzi B., Sauter C.
Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT)
Schott H, Horber D, Zahner R, Gowland P, Schwendener R. Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT). Antivir Chem Chemother 1994; 5:387-394.
Jan 1, 1994Synthesis, and some properties of amphiphilic dinucleoside phosphate derivatives of 3'-azido-2',3'-dideoxythymidine (AZT)
Jan 1, 1994Antivir Chem Chemother 1994; 5:387-394
Schott H., Horber Daniel, Zahner R., Gowland P., Schwendener R.